VIVUS, Inc. (NASDAQ:VVUS) Short Interest Down 5.1% in June

VIVUS, Inc. (NASDAQ:VVUS) was the target of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 562,600 shares, a decline of 5.1% from the May 15th total of 592,800 shares. Approximately 5.9% of the shares of the company are short sold. Based on an average daily volume of 43,800 shares, the days-to-cover ratio is presently 12.8 days.

Separately, ValuEngine lowered Wolverine World Wide from a “hold” rating to a “sell” rating in a research report on Monday, May 20th.

Shares of VVUS traded up $0.02 during midday trading on Friday, reaching $3.40. The stock had a trading volume of 10,545 shares, compared to its average volume of 27,625. VIVUS has a 52 week low of $2.15 and a 52 week high of $7.50. The firm has a 50 day moving average of $3.53. The firm has a market cap of $36.17 million, a P/E ratio of -0.98 and a beta of 1.85.

VIVUS (NASDAQ:VVUS) last announced its earnings results on Tuesday, April 30th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.42. The company had revenue of $16.15 million for the quarter. On average, equities research analysts anticipate that VIVUS will post -3.49 earnings per share for the current year.

Several hedge funds have recently modified their holdings of VVUS. Spark Investment Management LLC purchased a new position in shares of VIVUS during the first quarter valued at $98,000. Worth Venture Partners LLC grew its holdings in shares of VIVUS by 67.6% during the fourth quarter. Worth Venture Partners LLC now owns 50,292 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 20,292 shares in the last quarter. Alambic Investment Management L.P. purchased a new position in shares of VIVUS during the first quarter valued at $51,000. Finally, Sterling Investment Advisors Ltd. purchased a new position in shares of VIVUS during the first quarter valued at $42,000. Institutional investors and hedge funds own 15.61% of the company’s stock.


VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.

Featured Story: How does equity income fit into an investing strategy?

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with's FREE daily email newsletter.